Ensysce Biosciences (ENSC) Total Debt (2019 - 2025)

Ensysce Biosciences (ENSC) has reported Total Debt for 7 consecutive years, with $613416.0 the latest figure, recorded in Q4 2025.

• On a quarterly basis, Total Debt rose 1.67% year-over-year to $613416.0 in Q4 2025; TTM through Dec 2025 was $613416.0, a 1.67% increase from a year earlier, with the FY2025 full-year figure at $613416.0, up 1.67% from the prior year.
• Total Debt was $613416.0 for Q4 2025 at Ensysce Biosciences, down from $775404.0 in the prior quarter.
• Over five years, Total Debt peaked at $29.9 million in Q4 2021 and troughed at $466055.0 in Q2 2021.
• A 5-year average of $5.1 million and a median of $870259.0 in 2023 frame the typical range for Total Debt.
• Across the five-year window, Total Debt surged 1261.34% in 2021 and plunged 95.74% in 2023, its largest moves.
• Over 5 years, Total Debt stood at $29.9 million in 2021, then sank by 71.03% to $8.7 million in 2022, then tumbled by 80.29% to $1.7 million in 2023, then plunged by 64.71% to $603320.0 in 2024, then gained by 1.67% to $613416.0 in 2025.
• The last three Total Debt figures came in at $613416.0 (Q4 2025), $775404.0 (Q3 2025), and $849042.0 (Q2 2025), per Business Quant data.